Schunk Group Acquires Majority Stake in OptoTech


L-R: Peter R. Manolopoulos, Schunk Group,
Roland Mandler, OptoTech, Jens Schaefer,
OptoTech and Dr. Arno Roth CEO Schunk Group.

HEUCHELHEIM and WETTENBERG, Germany—The Schunk Group, a diversified technology company based in Heuchelheim, Germany, has acquired 51 percent of the shares in the optical machinery manufacturer OptoTech. The terms of the deal were not announced. OptoTech is now a division of the Schunk Group.

“In terms of technology, OptoTech is a very interesting company. It is a really good fit for the technology group Schunk due to its position as one of the technological and process engineering world market leaders in optical machinery manufacturing,” said Dr. Arno Roth, CEO of the Schunk Group, adding that that the optics industry is a growth market that offers Schunk further growth opportunities by investing in OptoTech.

Roland Mandler, founder and managing director of OptoTech, commented, “With the world’s most comprehensive product portfolio, OptoTech serves all manufacturing sectors from precision optics and ophthalmic lenses. OptoTech always offers complete manufacturing solutions. Schunk's investment puts OptoTech in a good starting position for further global growth and long-term development. Our customers will also profit from this.”

OptoTech headquarters in Wettenberg, Germany
OptoTech manufactures and markets machinery, services, measurement technology and coating systems as well as software, spare parts and consumables for the optical industry on a worldwide basis. The company was founded in 1985 and is headquartered in Wettenberg, Germany. Additional sites include Jena, Germany, Bellach, Switzerland, Milan, Hong Kong and Mumbai, as well as Palm, Pa. and Germantown, Wis. in the U.S.

Schunk was founded in Germany in 1913. It has developed into a worldwide technology concern with 60 locations in 29 countries, with sales of $1.4 billion and over 8,000 employees. It is active in many industries including automotive, electronics, aerospace and pharmaceuticals.